

Endocrine Abstracts

September 2022 Volume 83 ISSN 1479-6848 (online)





ESE Young Endocrinologists and Scientists (EYES) 2022


2-4 September 2022, Zagreb, Croatia











CONTENTS

ESE Young Endocrinologists and Scientists (EYES) 2022

Adrenal and Cardiovascular

Steroidomic approach for the characterization of patients with non-alcoholic fatty liver disease
to investigate metabolic risk in benign adrenal tumours with mild autonomous cortisol secretion
Looking for fingerprints of increased susceptibility to adrenal crises
Effects of Fibroblast factor 21 to adrenal renewal after chronic hypercortisolism
Bilateral primary aldosteronism prediction by Integer scoring system
Adrenal venous sampling in tertiary centre from 2015 to 2022
Poster
Prader-Willi syndrome proteins NDN and MAGEL2 are implicated in HPA axis regulation AP1
Autoimmune Polyglandular Syndrome Type 1 in siblings: assembling the jigsaw puzzle AP2
Recurrent paraganglioma in patient with aneurysmal disease
Malignant PPGLs - diagnosis and treatment challenges in a developing country-case series presentation AP4
Is it time for age and sex specific diagnostic criteria for patients with adrenal incidentalomas? AP5 Interplay of MYC and HIF signaling in pheochromocytomas and paragangliomas: Impact on the differentiation
and aggressiveness
Thyroid
Oral
Does mild form of subclinical hypothyroidism needs treatment?
Grant 2021" project
Combined levothyroxine/liothyronine therapy improves quality of life in hypothyroid thyroidectomized patients TO3
Should we reduce the number of fine-needle aspirations of thyroid nodules?
Is our recommendation to quit smoking considered in patients with Graves' Disease and Graves' Orbitopathy? TO5
Poster
The impact of lockdown on thyroid hormone metabolism in patients on levothyroxine replacement therapy
residing in Adjara
Unilateral Graves Orbitopathy-case report
Possible factors of hypercalcitoninemia in a benign nodular thyroid disease
Interplay between thyroid, amiodarone and heart - case presentation
of pregnancy, and thyrotoxicity development in offspring
Thyroid parameters changes in mother-newborn pairs living in a selenium deficient environment TP6
Therapeutic challenge in patient with ventricular septal defect, atrial fibiliation and thyreotoxicosis: Case report TP7
Endocrine-related Cancer
Oral
Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and
transcription of key oncogenic genes
Ablation of Znrf3 & Trp53 induces metastatic adrenocortical carcinoma in mice
Hypothalamus-pituitary-adrenal axis recovery after adjuvant mitotane treatment in patients with
adrenocortical carcinoma - a retrospective study

Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma (ACC)
adrenocortical carcinoma?
Poster
Synchronous eutopic and ectopic papillary thyroid carcinoma
Calcium and Bone
Oral
Hypercalcemia during pregnancy is associated with worse outcomes but not fetal loss
with β-thalassemia
Poster
Severe hypomagnesemia due to chronic diarrhea - a case report
adenomas - Clinical case
Diabetes, Obesity, Metabolism and Nutrition
Oral
Relation of HLA system genes in patients with type 1 diabetes and other autoimmune diseases DOMNO1 Placental Signalling Contributes to Adipokine Dysregulation and Systemic Insulin Resistance in Gestational
Diabetes Mellitus
glycemic control and low glycemic variability
a big data approach
Poster
Does phase angle analysis in overweight women be a surrogate marker of insulin resistance?
Reproductive and Developmental Endocrinology
Oral
Follicle stimulating hormone is efficient in increasing sperm parameters in idiopathic infertility

Which sperm parameter limits could really guide the clinical decision in assisted reproduction? RI Comparison of eunuchoid skeletal proportions in male hypogonadism between men with congenital hypogonadotropic hypogonadism (CHH) and Klinefelter Syndrome (KS)	DO4 DO5
Poster	
Late-discovered mosaic Klinefelter syndrome with severe osteoporosis and obesity	DP1 DP2
Reliability of patient's auto-report on the regularity of their menstrual cycle	DP4 DP5 DP6
	DP7
Pituitary and Neuroendocrinology	
Oral	
Leukocyte telomere length and neuregulin-4 levels in female patients with acromegaly: Relationship between disease activation and body fat distribution	NO1
of ESE guidelines	
Cardiovascular parameters and endothelial dysfunction in Cushing's Syndrome following remission: A prospective study	NO4
a single centre retrospective study	
Poster	
Newly diagnosed diabetes mellitus in an untreated hypopituitary patient	NP2 NP3
Environmental Endocrinology	
Oral	
Influence of mercury on thyroid hormone levels in the Serbian population - Benchmark dose approach El Influence of exposure to metaloestrogen - selenium on Leydig cell epigenetic status	EO2
supply for mothers and newborns	

Oral

T01

Does mild form of subclinical hypothyroidism needs treatment? Velkoska Nakova V¹, Krstevska B², Volkanovska Ilijevska C⁵ Stevchevska A³, Muca A³, Todorovska B³ & Boshevski M ¹Clinical Hospital, Stip, R.N.Macedonia, Internal medicine; ²Internal Medical Center "Srce", Skopje, R.N.Macedonia, Internal medicine; ³University Clinic of Endocrinology, Diabetes and Metabolic Disorders, Skopje, R.N.Macedonia, Endocrinology Department; ⁴University Clinic of Cardiology, Skopje, R.N. Macedonia, Cardiology department

Background

Overt hypothyroidisms warrants L-T4 treatment, but treatment in subclinical hypothyroidism (ScH), especially in mild form of ScH (TSH between 4,2-10mU/l and normal free thyroxine) is unknown.

Objectives

To compare the presence of risk factors for atherosclerosis in patients with mild form of ScH to euthyroid subjects.

Methods

Prospectively 67 consecutive patients with newly diagnosed ScH, and 30 healthy subjects were recruited from the outpatient department of University clinic of endocrinology in Skopje, R. of N. Macedonia. Measurement of thyroid hormones, thyroid antibodies, blood pressure, lipids, and carotid intima media thickness (CIMT) were performed in all patients.

Results

Mean TSH value in ScH group was 8.71 ± 1,9 mU/l. TSH value above 7mU/l was associated and positively correlated with symptoms of hypothyroidism. Prevalence of hypertension in ScH group was higher than the control group (35.4% vs. 13.3%, P = 0.03), with a 3.5 times higher risk for hypertension (OR = 3,5 95%CI 1,1 - 11,4). In patients with mild form of SCH statistical significant difference in percentages of patients with arterial hypertension, hypertriglyceridemia, and values of total cholesterol/HDL-C and LDL/HDL above upper reference value were found (33.9 vs. 13.3%, 33.9 vs. 10%, 26.5 vs. 6.9%, 30.6% vs. 10.3%, respectively P < 0.05). Mean CIMT was statistically significantly higher in ScH patients than the control group (0.61 \pm 0.1 vs. 0,56 \pm 0,1 mm, P = 0.03), but not different between the mild form of ScH and control group (P =0.08). Positive thyroid antibodies in the ScH group have no statistically significant influence on the CIMT.

In a small study, mild form of ScH was associated with higher risk for atherosclerosis, so these patients may benefit with L-T4 treatment. Key words. Subclinical hypothyroidism, risks factors, atherosclerosis, carotid intima media thickness

DOI: 10.1530/endoabs.83.TO1

TO2

Subacute thyroiditis (SAT) during the COVID-19 pandemic: prelimi-

Metabolic and Neural Sciences; Azienda Ospedaliero-Universitaria of Modena, Unit of Endocrinology, Department of Medical Specialties; Azienda Ospedaliero-Universitaria of Bologna, Division of Endocrinology and Diabetes Prevention and Care, Department of Medical and Surgical Sciences (DIMEC); ⁴University of Milan, School of Specialisation in Endocrinology; ⁵University of Milan, Department of Clinical Sciences and Community Health; ⁶Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Endocrinology

Background

A possible association between severe acute respiratory syndrome coronavirus (SARS-CoV)-2 pandemic and subacute thyroiditis (SAT) has been reported. Objectives

To evaluate SAT clinical characteristics, correlating them to virus exposure and/or vaccine and to evaluate thyroid function according to the length of time

We performed a prospective, observational, multi-centre study, considering three Italian centres. Patients with documented SAT diagnosis were enrolled from November 2020 to May 2022 and followed up for 12 months. SARS-CoV-2 infection (i.e. positive rhino-pharyngeal swab obtained within 3 months before SAT onset) and vaccination were recorded. This interim analysis was performed considering the visit performed at diagnosis.

A total of 67 subjects (79.1% F, 20.9% M) were enrolled (age: 49.9 + 12.9 years). The cohort was divided considering the time between symptoms onset and endocrinological evaluation: Group1 included patients who underwent visit within 15 days (44.8%), whereas Group2 those who delayed visit beyond 15 days (55.2%). No difference in inflammation indexes and thyrotoxicosis rate (70.0% vs 70.3%, P = 0.381) was found between groups. Hypothyroidism rate was higher in Group2 than in Group1 (8.1% vs 0.0%, P = 0.004). The entire cohort was divided according to either SARS-Cov2 infection (13 patients-19.4%) or vaccination (23 patients-34.3%). Thyrotoxicosis rate and inflammation indexes were not significantly different between patients with or without SARS-Cov2 infection and/or vaccination. At multinomial logistic regression analyses, thyrotoxicosis was predicted by erythrocyte sedimentation rate (ESR) elevation (P < 0.001), SARS-CoV-2-vaccination (P = 0.002) and respiratory symptoms (P < 0.001)

Conclusions

Results

Neither SARS-CoV-2 infection nor vaccination affected the clinical SAT presentation. However, SAT-related thyrotoxicosis was predicted by ESR elevation, vaccination, and respiratory symptoms.

DOI: 10.1530/endoabs.83.TO2

Combined levothyroxine/liothyronine therapy improves quality of life

in hypothyroid thyroidectomized patients
Corleto R. ^{1, 2}, Boselli G. ^{1, 2}, Margiotta G. ^{1, 2}, Monzani M. L. ^{1, 2}, Craparo A. ^{1, 2}, Locaso M. ^{1, 2}, Sperduti S. ^{1, 3}, Roy N¹, Simoni M. ^{1, 2, 3}, Rochira V. ^{1, 2}, Santi D. ^{1, 2} & Brigante G. ^{1, 2}

¹ University of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences; ²Azienda Ospedaliero-Universitaria of Modena, Unit of Endocrinology, Department of Medical Specialties; University of Modena and Reggio Émilia, Center for Genomic Research

Introduction

Despite normal thyroid stimulating hormone (TSH) serum levels, 10% of hypothyroid patients treated with LT4 complain of hypothyroidism symptoms, likely linked to decreased availability of free triiodothyronine (fT3). Thus, combined levothyroxine/liothyronine (LT4/IT3) therapy was suggested to ensure a more physiological balance in peripheral tissues

To evaluate the effectiveness of combined LT4/IT3 therapy in thyroidectomized subjects, considering peripheral markers and quality of life.

An interim analysis of a prospective, randomized, placebo-controlled, doubleblinded clinical trial was performed. Totally thyroidectomized patients treated with LT4 and with TSH levels within reference range in the previous three months were enrolled and randomized in two groups: combined LT4/IT3 therapy (study group) and LT4+placebo (control group). Lipid profile, sex hormone binding globulin, osteocalcin, C-terminal telopeptide and bone alkaline phosphatase were evaluated as peripheral markers. Quality of life was evaluated by ThyPRO 39 questionnaire.

Results

139 patients (age 55.6+12.1 years) were enrolled, 70 in the study and 69 in the control group. Combined LT4/IT3 therapy resulted in more frequent iatrogenic thyrotoxicosis than LT4 monotherapy (9.8% vs 2.2%; P < 0.05), requiring more frequent dose adjustments (44.5% vs 22.5%; P < 0.001). Peripheral markers neither changed between study and control groups, nor among visits. Combined therapy improved quality of life, measured by a reduction in anxiety (P = 0.019), depression (P = 0.037), emotional susceptibility (P = 0.034) and item 12 (P = 0.034) 0.005) from baseline to visit 3, while no significant differences were detected in controls.

Conclusion

Six months of combined therapy significantly improved quality of life, but did not lead to a change in peripheral tissue markers. However, subjects treated with LT4/IT3 therapy require more dose adjustment and are at higher risk of overtreatment.

DOI: 10.1530/endoabs.83.TO3